ElectroCore Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
5analysts covering
FY Revenue (est.)
$41.9Mnext fiscal year
FY EPS (est.)
-$1.48next fiscal year
Monitoring Framework
Key Performance Indicators
Quarterly Net Sales Quarterly9.6MTarget: Approximately 30% annual growth over full-year 2025
Gross Profit Margin Quarterly87.0%Target: Maintain or expand high-80s margin profile
Adjusted EBITDA Net Loss Quarterly-2.3MTarget: Achieve positive adjusted EBITDA
Watch Items
- U.S. Department of Veterans Affairs (VA) Channel ConcentrationTrigger: VA sales representing over 70% of total prescription revenueAction: Accelerate commercialization of Truvaga direct-to-consumer products and expand Quell Fibromyalgia sales to diversify revenue streams.
- Cash Burn and Going Concern RiskTrigger: Total cash, cash equivalents, and marketable securities falling below $8.8 millionAction: Monitor operating cash outflows (currently $3.0 million utilized in Q1 2026) and evaluate additional non-dilutive funding or equity financing options.
Research as of 20 Jun 2026